Introduction
Functional precision medicine aims to expand the landscape of effective drug treatment options beyond standard of care through additional insights from ex vivo phenotypic drug response data. In our previous work, we have demonstrated the clinical feasibility of Optim.AI™, a combinatorial functional precision medicine platform, in identifying effective and resistant treatment options for non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), and soft tissue sarcoma. This study further investigates the clinical utility and concordance of Optim.AI™ in predicting treatment sensitivity or resistance in a variety of hematological and solid cancers processed at KYAN’s clinical laboratory, with notable case studies highlighted.
What you will see in the poster:
- Our methodology
- Retrospective Concordance Analysis of Clinical Samples
- Three Patient Cases: NHL, AML & Breast Cancer.
Fill the the form now to download the poster.